FDA: Cylert risks outweigh benefits

The FDA has determined that the overall risks posed by Abbott Laboratories' Cylert for ADHD outweigh its benefits. "The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug," said an announcement on the agency's Web site. Abbott announced last March that it would stop making the drug because of declining sales.

- read this FDA alert for more